Tempus Wealth Planning LLC Increases Position in Pfizer Inc. (NYSE:PFE)

Tempus Wealth Planning LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 35.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 24,768 shares of the biopharmaceutical company’s stock after acquiring an additional 6,467 shares during the period. Tempus Wealth Planning LLC’s holdings in Pfizer were worth $657,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter worth about $26,000. Gladius Capital Management LP lifted its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the last quarter. Quarry LP purchased a new stake in Pfizer during the second quarter valued at approximately $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Pfizer in the third quarter valued at approximately $35,000. Finally, Joseph Group Capital Management increased its position in shares of Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

PFE has been the subject of a number of recent analyst reports. Bank of America reissued a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim lowered their price target on Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Finally, Truist Financial cut their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Trading Down 1.1 %

Shares of NYSE:PFE opened at $26.23 on Tuesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business has a 50 day moving average of $26.27 and a two-hundred day moving average of $27.85. The company has a market capitalization of $148.62 billion, a PE ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.